Table 8. Summary of novel antileukemic... | American Society of Hematology

Table 8.

Summary of novel antileukemic agents tested in combination with imatinib in vitro.

Agent	Molecular Mechanism(s)	Refs.
Abbreviations: As₂O₃, arsenic trioxide; hsp90, heat-shock protein 90; PS341, proteasome inhibitor 341; MAPK, mitogen-activated protein kinase, 17-AAG, Allylamino-17-demethoxygeldanamycin; TRAIL, tumor necrosis factor α-related apoptosis-inducing ligand.
17-AAG	hsp90 chaperone function inhibition	53
Adaphostin	tyrosine kinase inhibition	50
AG490	tyrosine kinase inhibition	51
As₂O₃	induction of mitochondrial damage Bcr-Abl downregulation	55, 56
Bestatin, actinonin	aminopeptidase inhibition	64
Decitabine	DNA hypomethylation	40
Homoharringtonine	inhibition of protein synthesis	34
Leptomycin	nuclear entrapment of Bcr-Abl	65
PD184352	MAPK kinase inhibition	66
Wortmannin, LY294002	PI3-kinase inhibition	67
PS341	proteasome inhibition	68
SCH66336, L-744,832	farnesyl transferase inhibition	53, 54
TRAIL	induction of apoptosis	69
Trichostatin A	histone deacetylase inhibition	40

Agent	Molecular Mechanism(s)	Refs.
Abbreviations: As₂O₃, arsenic trioxide; hsp90, heat-shock protein 90; PS341, proteasome inhibitor 341; MAPK, mitogen-activated protein kinase, 17-AAG, Allylamino-17-demethoxygeldanamycin; TRAIL, tumor necrosis factor α-related apoptosis-inducing ligand.
17-AAG	hsp90 chaperone function inhibition	53
Adaphostin	tyrosine kinase inhibition	50
AG490	tyrosine kinase inhibition	51
As₂O₃	induction of mitochondrial damage Bcr-Abl downregulation	55, 56
Bestatin, actinonin	aminopeptidase inhibition	64
Decitabine	DNA hypomethylation	40
Homoharringtonine	inhibition of protein synthesis	34
Leptomycin	nuclear entrapment of Bcr-Abl	65
PD184352	MAPK kinase inhibition	66
Wortmannin, LY294002	PI3-kinase inhibition	67
PS341	proteasome inhibition	68
SCH66336, L-744,832	farnesyl transferase inhibition	53, 54
TRAIL	induction of apoptosis	69
Trichostatin A	histone deacetylase inhibition	40